NYSEAMERICAN:LCTX Lineage Cell Therapeutics (LCTX) Stock Price, News & Analysis → Warren Buffett's 'mystery stock' (From Stansberry Research) (Ad) Free LCTX Stock Alerts $1.06 +0.03 (+2.40%) (As of 10:06 AM ET) Add Compare Share Share Today's Range$1.04▼$1.0750-Day Range N/A52-Week Range$0.84▼$1.61Volume129,679 shsAverage Volume959,284 shsMarket Capitalization$201.07 millionP/E RatioN/ADividend YieldN/APrice Target$6.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartEarningsHeadlinesInsider TradesOwnershipShort InterestStock AnalysisAnalyst ForecastsChartEarningsHeadlinesInsider TradesOwnershipShort Interest Get Lineage Cell Therapeutics alerts: Email Address Lineage Cell Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside524.9% Upside$6.50 Price TargetShort InterestBearish5.77% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.01Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.26 out of 5 stars 3.5 Analyst's Opinion Consensus RatingLineage Cell Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageLineage Cell Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Lineage Cell Therapeutics' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted5.77% of the outstanding shares of Lineage Cell Therapeutics have been sold short.Short Interest Ratio / Days to CoverLineage Cell Therapeutics has a short interest ratio ("days to cover") of 11, which indicates bearish sentiment.Change versus previous monthShort interest in Lineage Cell Therapeutics has recently increased by 3.02%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldLineage Cell Therapeutics does not currently pay a dividend.Dividend GrowthLineage Cell Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LCTX. Previous Next 1.7 News and Social Media Coverage News SentimentLineage Cell Therapeutics has a news sentiment score of 0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Lineage Cell Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 6 people have searched for LCTX on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Lineage Cell Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Lineage Cell Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders28.10% of the stock of Lineage Cell Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions62.47% of the stock of Lineage Cell Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Lineage Cell Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Lineage Cell Therapeutics are expected to remain at ($0.12) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lineage Cell Therapeutics is -7.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lineage Cell Therapeutics is -7.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLineage Cell Therapeutics has a P/B Ratio of 2.97. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Wall Street StarThis Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industry About Lineage Cell Therapeutics Stock (NYSEAMERICAN:LCTX)Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ANP1, an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of debilitating hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.Read More LCTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LCTX Stock News HeadlinesMay 21 at 10:19 AM | finance.yahoo.comLineage Announces Updates to 2nd Annual Spinal Cord Injury Investor SymposiumMay 14, 2024 | markets.businessinsider.comBuy Rating on Lineage Therapeutics Backed by Roche Collaboration and Solid FinancialsMay 13, 2024 | americanbankingnews.comEquities Analysts Offer Predictions for Lineage Cell Therapeutics, Inc.'s FY2028 Earnings (NYSEAMERICAN:LCTX)May 10, 2024 | finance.yahoo.comQ1 2024 Lineage Cell Therapeutics Inc Earnings CallMay 10, 2024 | finance.yahoo.comLineage Cell Therapeutics Q1 2024 Earnings: Aligns with EPS Projections Amidst Revenue DeclinesMay 10, 2024 | finance.yahoo.comLineage Cell Therapeutics, Inc. (AMEX:LCTX) Q1 2024 Earnings Call TranscriptMay 9, 2024 | businesswire.comLineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 8, 2024 | markets.businessinsider.comBuy Rating for Lineage Cell Therapeutics as OpRegen Shows Durable Benefits for GA PatientsMay 6, 2024 | markets.businessinsider.comMaintained Buy Rating for Lineage Cell Therapeutics on Robust Clinical Trial Results and Strong Partnership with RocheMay 6, 2024 | businesswire.comOpRegen® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation SummitMay 2, 2024 | businesswire.comLineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024April 30, 2024 | businesswire.comLineage Receives Grant From California Institute for Regenerative Medicine (CIRM)April 29, 2024 | businesswire.comLineage Announces Changes to Board of DirectorsApril 19, 2024 | finance.yahoo.com12 Cheap Foods With Anti-Aging Properties That Longevity Scientists Swear ByApril 1, 2024 | finance.yahoo.comLineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate DevelopmentMarch 28, 2024 | msn.com5 Simple Wealth-Building Tips For This Generation's Forward-ThinkersMarch 19, 2024 | markets.businessinsider.comOptimistic Buy Rating for Lineage Cell Therapeutics Ahead of OpRegen Study Data ReleaseMarch 18, 2024 | seekingalpha.comPuma Biotechnology dips after dismissal of its suit was granted by a federal judgeMarch 18, 2024 | finance.yahoo.com15 Best Anti-Aging Foods for Youthful SkinMarch 18, 2024 | finance.yahoo.comLineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor SymposiumMarch 18, 2024 | businesswire.comLineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor SymposiumMarch 14, 2024 | finance.yahoo.comBillionaire Ken Fisher and Corporate Insiders Are Buying These 10 StocksMarch 13, 2024 | finance.yahoo.comRG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation SummitMarch 11, 2024 | finance.yahoo.comRG6501 (OpRegen®) Preclinical Engraftment Results to Be Presented at 2024 Association for Research in Vision and Ophthalmology MeetingMarch 11, 2024 | markets.businessinsider.comBuy Rating Affirmed for Lineage Cell Therapeutics Amidst Promising Regenerative Therapy AdvancementsSee More Headlines Receive LCTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lineage Cell Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNYSEAMERICAN:LCTX CUSIPN/A CIKN/A Webwww.lineagecell.com Phone(442) 287-8963Fax510-521-3389Employees68Year FoundedN/APrice Target and Rating Average Stock Price Target$6.50 High Stock Price Target$7.00 Low Stock Price Target$6.00 Potential Upside/Downside+525.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.14) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-21,490,000.00 Net Margins-295.59% Pretax Margin-295.30% Return on Equity-34.92% Return on Assets-22.14% Debt Debt-to-Equity RatioN/A Current Ratio2.71 Quick Ratio2.71 Sales & Book Value Annual Sales$8.94 million Price / Sales21.96 Cash FlowN/A Price / Cash FlowN/A Book Value$0.35 per share Price / Book2.97Miscellaneous Outstanding Shares188,800,000Free Float135,746,000Market Cap$196.35 million OptionableNot Optionable Beta1.39 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Brian M. Culley M.A. (Age 53)M.B.A., CEO, President & Director Comp: $944.15kMs. Jill Ann Howe (Age 47)CFO & Principal Financial and Accounting Officer Comp: $125.52kMr. George A. Samuel III (Age 43)J.D., General Counsel & Company Secretary Comp: $560.95kIoana C. HoneDirector of Investor RelationsMs. Brandi L. Roberts CPA (Age 50)M.B.A., Consultant Comp: $407.45kMr. William Annett MBA (Age 70)President & CEO of OncoCyte Corporation Comp: $53.2kDr. Rami Skaliter Ph.D. (Age 66)Chief Executive Officer of Cell Cure Neurosciences Ms. Alexandra HernandezSenior Director of Finance & ControllerDr. Harold D. Waitz (Age 82)Vice President of Regulatory Affairs & Quality Control Comp: $90kMore ExecutivesKey CompetitorsElevation OncologyNASDAQ:ELEVFennec PharmaceuticalsNASDAQ:FENCKodiak SciencesNASDAQ:KODCentury TherapeuticsNASDAQ:IPSCAdverum BiotechnologiesNASDAQ:ADVMView All CompetitorsInsiders & InstitutionsComerica BankBought 250,000 shares on 5/17/2024Ownership: 0.133%Price T Rowe Associates Inc. MDBought 70,418 shares on 5/15/2024Ownership: 0.085%Vanguard Group Inc.Sold 10,916 shares on 5/10/2024Ownership: 4.435%Fifth Third Wealth Advisors LLCBought 20,000 shares on 4/16/2024Ownership: 0.011%Don M BaileyBought 96,155 shares on 2/8/2024Total: $100,001.20 ($1.04/share)View All Insider TransactionsView All Institutional Transactions LCTX Stock Analysis - Frequently Asked Questions Should I buy or sell Lineage Cell Therapeutics stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Lineage Cell Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LCTX shares. View LCTX analyst ratings or view top-rated stocks. What is Lineage Cell Therapeutics' stock price target for 2024? 2 brokerages have issued 12 month price targets for Lineage Cell Therapeutics' shares. Their LCTX share price targets range from $6.00 to $7.00. On average, they predict the company's stock price to reach $6.50 in the next twelve months. This suggests a possible upside of 524.9% from the stock's current price. View analysts price targets for LCTX or view top-rated stocks among Wall Street analysts. How were Lineage Cell Therapeutics' earnings last quarter? Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) announced its quarterly earnings results on Thursday, May, 9th. The company reported ($0.04) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.04). The firm earned $1.44 million during the quarter, compared to analysts' expectations of $2.22 million. Lineage Cell Therapeutics had a negative net margin of 295.59% and a negative trailing twelve-month return on equity of 34.92%. What other stocks do shareholders of Lineage Cell Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Lineage Cell Therapeutics investors own include Matinas BioPharma (MTNB), Bionano Genomics (BNGO), ADMA Biologics (ADMA), Novan (NOVN), Pennsylvania Real Estate Investment Trust (PEI), CNBX Pharmaceuticals (CNBX), Enerplus (ERF), KushCo (KSHB) and Zosano Pharma (ZSAN). Who are Lineage Cell Therapeutics' major shareholders? Lineage Cell Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (4.44%), Comerica Bank (0.13%), Price T Rowe Associates Inc. MD (0.09%) and Fifth Third Wealth Advisors LLC (0.01%). Insiders that own company stock include Angus C Russell, Brian M Culley, Broadwood Partners, LP, Dipti Amin, Don M Bailey, Gary S Hogge and Michael H Mulroy. View institutional ownership trends. How do I buy shares of Lineage Cell Therapeutics? Shares of LCTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSEAMERICAN:LCTX) was last updated on 5/21/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsDoes this make you sick?Allegiance Gold[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 MediaBill Gates is all about this tiny $2 stockTimothy SykesThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldBill Clinton Backing Biden Replacement???The Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lineage Cell Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.